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Abstract
 
Interleukin (IL)-4–secreting tumors are rejected in mice, an effect that is thought to be immune
mediated. However, solid tumors are embedded in a stroma that often contains tumor-promoting
fibroblasts, a cell population whose function is also affected by IL-4. Here we show that IL-4–
 
secreting tumors grew undiminished in IL-4 receptor (R)–deficient (IL-4R
 

 
/
 

 
) mice. In IL-4R
 

 
/
 

 
mice they were long-term suppressed in the absence of T cells but complete rejection required
T cells, compatible with the assumption that hematopoietic cells needed to respond to IL-4.
Surprisingly, bone marrow (BM) chimeric mice revealed that IL-4R expression exclusively
on non-BM–derived cells was sufficient for tumor rejection. Fibroblasts in the tumor stroma
were identified as a target cell type for IL-4 because they accumulated in IL-4–secreting tumors
 
and displayed an activated phenotype. Additionally, coinjection of IL-4R
 

 
/
 
 
 
but not IL-
4R
 

 
/
 
 
 
fibroblasts was sufficient for the rejection of IL-4–secreting tumors in IL-4R
 

 
/
 
 
 
mice.
Our data demonstrate a novel mechanism by which IL-4 contributes to tumor rejection and
show that the targeted modulation of tumor-associated fibroblasts can be sufficient for tumor
rejection.
Key words: IL-4 receptor • knockout mice • bone marrow transplantation • 
angiogenesis • collagen
 
Introduction
 
The antitumor effect of IL-4 was discovered more than a
decade ago (1) and many studies suggested that IL-4–secreting
tumors were rejected in an immunological manner (2, 3).
The importance of particular cell types for IL-4–mediated
tumor rejection was concluded from their accumulation
within the tumor or from impaired tumor rejection after
their depletion in vivo. These experiments demonstrated
that tumor rejection occurred in a biphasic manner. Long-
term suppression but usually not complete rejection was
observed in the absence of T cells. Granulocytes were
made responsible, at least in part, for inhibition of tumor
burden (4) and CD8
 
 
 
T cells for complete rejection of IL-4–
secreting tumors (5–7). However, granulocyte depletion by
antibodies only partially restored tumor growth and experi-
ments were terminated too early to decide whether IL-4–
secreting tumors would have been rejected despite the
depletion of granulocytes. This indicated that there might
be other cell types that inhibited tumor growth. Impor-
tantly, it has not been analyzed whether tumor rejection
resulted from a direct or indirect action of IL-4 on immune
cells and whether nonhematopoietic cells, e.g., tumor
stroma cells, were involved.
Solid tumors are embedded in a stroma that is usually
composed of inflammatory cells as well as non-BM–derived
cells. Fibroblasts are the predominant stromal cell in pri-
mary carcinomas (8, 9). Their almost ubiquitous presence in
tumors suggests that they might support tumor growth.
Indeed, in a number of tumor transplantation models it was
shown that coinjection of fibroblasts with tumor cells of differ-
ent malignancies consistently accelerated tumor growth or
facilitated tumor take (10–15). This emphasizes that in addi-
tion to genetic alterations of tumor cells, interactions between
tumor cells and fibroblasts are critically important for tumor
growth (8). Fibroblasts express IL-4R (16, 17) and respond to
IL-4 with increased proliferation (17, 18) and synthesis of
extracellular matrix proteins (17, 19–22). Given that (a) IL-
4Rs are expressed on most, if not all, cell types (16), and (b)
that IL-4 mediates its antitumor effect locally rather than
systemically (1), we asked whether non-BM–derived stromal
cells contribute to IL-4–mediated tumor rejection. Surpris-
ingly, IL-4 responsiveness exclusively by tumor stroma fibro-
blasts was sufficient for rejection of IL-4–secreting tumors.
 
The online version of this article contains supplemental material.
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Materials and Methods
 
Mice, Cell Lines, Tumor Cell Injection, and Histology.
 
BALB/c
mice were purchased from Charles River Laboratories. RAG2
 

 
/
 

 
(C.129(B6)-Rag2 tm1 N12) BALB/c mice were purchased
from Taconic. IL-4–deficient (IL-4
 

 
/
 

 
) IL-4R 
 
 
 
chain–deficient
(IL-4R
 

 
/
 

 
; reference 23) and RAG2
 

 
/
 

 
/IL-4R
 

 
/
 
 
 
double
knockout BALB/c mice were provided by N. Noben-Trauth
(George Washington University, Washington, DC) and bred in
our animal facility. J558L is a BALB/c plasmacytoma cell line. Its
Il-4–secreting derivative (J558-IL-4) has been described (6).
Within 24 h of culture, 10
 
6 
 
J558-IL-4 cells secrete 6.3 ng/ml IL-4
as determined by ELISA (BD Biosciences). The tumor cell line
was cultured in RPMI 1640 plus 10% FCS, penicillin/streptomy-
cin, MEM, and 2-ME (50 
 

 
M; complete RPMI) with 1 mg/ml
G418. For the analysis of tumor growth in vivo, mice were in-
jected s.c. with 1–2 
 
 
 
10
 
6 
 
cells. The tumor diameter was deter-
mined as the mean of the largest diameter and the diameter at
right angle. Mice that developed a tumor of 1 cm in diameter
were scored as tumor positive. Mice shown as tumor free at the
end of the experiment had completely rejected the tumor. For
the immunohistological analysis of tumor tissues from WT and
IL-4R
 

 
/
 
 
 
mice, 10
 
7 
 
tumor cells were injected s.c. 6 d later, tumor
tissues were removed and cryo sectioned. To detect fibroblasts/
extracellular matrix and collagen I, the monoclonal antibodies
ER-TR7 (BMA Biomedicals; reference 24) and anti–collagen I
(Dunn Labortechnik) were used, respectively. Subsequent alka-
line phosphatase staining was performed by standard technique
using enzyme-coupled secondary antibodies from Jackson Immu-
noResearch Laboratories.
 
Generation of BM Chimeras.
 
BM was harvested from femurs
of WT and IL-4R
 

 
/
 
 
 
BALB/c mice and washed twice in PBS.
5 
 
 
 
10
 
6 
 
BM cells in PBS were injected i.v. into lethally irradiated
(9 Gy) WT or IL-4R
 

 
/
 
 
 
recipient mice on the same day. After
reconstitution, all mice were maintained on antibiotic water for
4 wk. Chimeric mice were injected with tumor cells 10 and 17 wk
after reconstitution. To test whether peripheral lymphocytes were
derived from donor or recipient BM, MHC class II up-regulation
in response to IL-4 was determined on splenic B cells. For this
purpose, single cell suspensions were prepared from spleens of the
indicated mice and cultured for 16 h at 2 
 
 
 
10
 
6
 
/ml with or with-
out 2 ng/ml recombinant mouse IL-4 (BD Biosciences) in com-
plete RPMI. Cells were incubated with anti–B220-PE (RA3-
6B2) and anti–I-A
 
d
 
/I-E
 
d
 
–FITC (2G9) and analyzed using Coulter
EPICS-XL (Coulter Electronics). Flow cytometry of spleen cells
of chimeric mice using an IL-4R–specific mAb confirmed the re-
sults. Additionally, 
 
il4r
 
-specific PCR analysis with genomic DNA
from peripheral blood cells confirmed the results obtained by
flow cytometry. Reconstituted mice had normal CD4
 

 
, CD8
 

 
,
and B220
 
 
 
cell numbers compared with untreated WT and IL-
4R
 

 
/
 
 
 
mice (unpublished data).
 
Generation of Fibroblasts and Coinjection with J558-IL-4 Cells.
 
Lungs from WT or IL-4R
 

 
/
 
 
 
mice were minced and incubated
for 1 h at 37
 

 
C in RPMI plus 5% FCS with 1 mg/ml collagenase
D (Roche Diagnostics). Cells were further separated by meshing
through a 70-
 

 
M nylon filter. Single cell suspensions were
washed twice with PBS and cultured in DMEM plus 10% FCS,
penicillin/streptomycin, MEM, and 2-ME (50 
 

 
M) for 24 h.
Nonadherent cells were removed and adherent cells were pas-
saged every 3–5 d. After eight passages, 85–95% of the cultured
cells were positive for fibronectin and collagen I, suggesting that
the majority of the cells were fibroblasts (unpublished data). For
the coinjection with J558-IL-4 cells, 10
 
6 
 
WT or IL-4R
 

 
/
 
 
 
fibro-
blasts, respectively, were mixed with 10
 
6 
 
J558-IL-4 cells, injected
 
s.c. in the abdominal region of IL-4R
 

 
/
 
 
 
mice and tumor growth
was measured.
 
Online Supplemental Material.
 
All experiments related to Fig.
1 are shown in Table SI, which is available at http://www.jem.
org/cgi/content/full/jem.20030849/DC1.
 
Results
 
Biphasic Rejection of IL-4–secreting Tumors.
 
First, we
confirmed and extended that long-term suppression of IL-
4–secreting tumors occurred in the absence of T cells but
that complete rejection required their presence. As shown
in Fig. 1 and published previously (6), IL-4–secreting
BALB/c plasmacytoma J558L cells (J558-IL-4) were re-
jected in WT BALB/c mice. IL-4R
 

 
/
 
 
 
BALB/c and IL-
4R
 

 
/
 

 
/RAG2
 

 
/
 
 
 
mice developed J558-IL-4 tumors
within 8–10 d after tumor cell injection on the average. To
exclude that IL-4R–independent effects inhibited the
growth of IL-4–producing tumors, the growth kinetics of
parental J558L tumors in WT mice (
 
n 
 
 
 
13) was compared
with that of J558-IL-4 cells in IL-4R
 

 
/
 
 
 
mice (
 
n 
 
 
 
17).
Except for one J558L tumor that required 31 d to grow to
1 cm in diameter, J558L and J558-IL-4 tumors reached this
size in 8.6 
 
	 
 
1.3 and 8.5 
 
	 
 
1.5 d, respectively (Table
SI, available at http://www.jem.org/cgi/content/full/jem.
20030849/DC1). This suggested that the antitumor effect of
IL-4 was entirely dependent on IL-4R expression by host
cells and, thus, resulted from a paracrine effect on host cells
rather than from an autocrine effect on tumor cells. IL-4 ex-
pression by the tumor cells was sufficient for tumor rejection
because IL-4
 

 
/
 
 
 
mice rejected J558-IL-4 cells (Fig. 1). In
RAG2
 

 
/
 
 
 
mice, J558-IL-4 tumor growth was strongly de-
layed. However, all mice finally developed tumors (Fig. 1).
This is in line with previous results showing that CD8
 
 
 
T
cells are essential for the rejection of J558-IL-4 tumors (6).
This shows that IL-4 mediated its antitumor effect in two
phases. Within the first weeks after tumor cell injection, IL-4R
expression by nonlymphoid cells was sufficient to prevent
rapid tumor formation, whereas lymphocytes were required
in the later phase to allow complete tumor rejection.
Figure 1. Biphasic rejection of
IL-4–producing tumor cells re-
quires host IL-4R but not IL-4.
BALB/c WT (wt; ), Rag2/
(), IL-4/ (), IL-4R/ (),
and RAG2//IL-4R/ mice
() were injected with 2  106
J558-IL-4 cells and tumor
growth was measured. One rep-
resentative experiment per ex-
perimental group (five to six mice per group) is shown. In total, 30
BALB/c (six experiments), 11 RAG2/ (two experiments), 17 IL-4/
(two experiments), 33 IL-4R/ (six experiments), and 11 RAG2//
IL-4R/ mice (two experiments) were analyzed. In three of the experi-
ments with J558-IL-4 cells in IL-4R/ mice, a group with parental
J558L cells in WT mice (n  13) was included showing no significant
difference in growth kinetics between the two groups. All experiments
are presented individually in Table SI, available at http://www.jem.org/
cgi/content/full/jem.20030849/DC1.
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Generation of IL-4R BM Chimeric Mice.
 
To identify the
cell types that contributed to IL-4–mediated tumor rejec-
tion, we generated BM chimeric mice expressing IL-4R
selectively on BM- or non-BM–derived cells. Lethally irra-
diated WT mice were reconstituted with BM cells from
WT (WT 
 

 
 
WT) or IL-4R
 

 
/
 
 
 
mice (IL-4R
 

 
/
 
 
 

 
 
WT)
and lethally irradiated IL-4R
 

 
/
 
 
 
mice were reconstituted
with BM cells from IL-4R
 

 
/
 
 
 
(IL-4R
 

 
/
 
 
 

 
 
IL-4R
 

 
/
 

 
) or
WT (WT 
 

 
 
IL-4R
 

 
/
 

 
) mice. To ensure complete donor
cell reconstitution, spleen cells from BM chimeric mice 10
wk after BM transplantation and untreated WT and IL-
4R
 

 
/
 
 
 
mice were cultured for 16 h with or without IL-4.
The up-regulation of MHC class II molecules on B cells in
 
response to IL-4 was determined by flow cytometry as an
indication for IL-4R expression. The histograms in Fig. 2,
A–F, show MHC class II expression profiles of B cells after
culture without (red lines) or with IL-4 (blue lines). B cells
from WT 
 

 
 
IL-4R/ mice up-regulated MHC class II
expression (histogram in Fig. 2 E), similar to B cells from
normal WT mice (histogram in Fig. 2 A) and WT 
 WT
chimeras (histogram in Fig. 2 C). In IL-4R/ 
 WT
mice, peripheral lymphocytes were also derived from do-
nor BM, since their B cells were unable to respond to IL-4
(Fig. 2 F, histogram) as observed for B cells from IL-4R/
mice (Fig. 2 B, histogram) and IL-4R/ 
 IL-4R/ chi-
meric mice (Fig. 2 D, histogram). The results were con-
firmed by flow cytometry for IL-4R expression on spleno-
cytes and by PCR analysis with genomic DNA from
peripheral blood that discriminated between donor and re-
cipient il4r alleles (unpublished data). This indicated that
the hematopoietic system was almost completely of donor
cell origin 10 wk after BM transplantation.
IL-4R Expression on Non-BM–derived Cells Is Sufficient
for Rejection of J558-IL-4 Cells. Next, we determined
whether the chimeric mice were able to reject J558-IL-4
tumors. WT 
 WT chimeras (Fig. 2 C) and normal WT
mice (Fig. 2 A) were injected with 2  106 J558-IL-4 cells
and tumor growth was measured. As shown in Fig. 2 C, all
WT 
 WT mice rejected tumors (10/10) as efficiently as
normal WT mice (10/10; Fig. 2 A), showing that tumor
rejection was not impaired in BM chimeras. To exclude
that tumors were rejected in BM chimeras due to the ex-
perimental procedure rather than IL-4R responsiveness,
IL-4R/ 
 IL-4R/ chimeras (Fig. 2 D) and normal IL-
4R/ mice (Fig. 2 B) were injected with J558-IL-4 cells.
As shown in Fig. 2, B and D, tumors grew rapidly and with
similar kinetics in both experimental groups (tumor rejec-
tion in 0/10 mice in both experimental groups). This dem-
onstrated that (a) tumor growth was not impaired in BM
chimeras, and that (b) IL-4R expression by host cells was
still required for the rejection of J558-IL-4 tumors.
Perhaps not surprising, IL-4R expression on BM-derived
cells was sufficient for tumor rejection. As shown in Fig.
2 E, WT 
 IL-4R/ mice rejected J558-IL-4 tumors (eight
out of nine), showing that IL-4R expression by BM-derived
cells was sufficient for IL-4–mediated tumor rejection in
most cases. However, it is important to note that tumors in
WT 
 IL-4R/ chimeras reached an average size of
0.7 cm in diameter before rejection. This was in contrast to
WT 
 WT mice (Fig. 2 C), in which the tumors remained
smaller before regression. These differences suggested that
IL-4R expression by non-BM–derived cells contributed to
tumor growth suppression. This interpretation was sup-
ported by the fact that tumor formation was completely pre-
vented in IL-4R/ 
 WT chimeras expressing IL-4R ex-
clusively on non-BM–derived cells (10/10; Fig. 2 F). This
demonstrated that IL-4R expression by non-BM–derived
cells was sufficient for rejection of IL-4–secreting tumors. It
should be mentioned that several tumor-free WT 
 IL-
4R/ mice developed a wasting syndrome that finally led
to their death between days 30 and 66 after tumor cell injec-
Figure 2. IL-4R expression on non-BM–derived cells is sufficient for
the rejection of J558-IL-4 cells. For the generation of BM chimeras, irra-
diated (9 Gy) BALB/c WT (wt) mice were reconstituted with BM cells
from (C) WT (WT 
 WT) or (F) IL-4R/ mice (IL-4R/ 
 WT).
Irradiated IL-4R/ mice were reconstituted with BM cells from (D)
IL-4R/ (IL-4R/ 
 IL-4R/) or (E) WT (WT 
 IL-4R/) mice.
(C–F) 2  106 J558-IL-4 cells were injected s.c. in the indicated BM
chimeras, (A) untreated WT, and (B) IL-4R/ mice. Pooled results from
two independent experiments performed 10 and 17 wk after reconstitution
are shown. In total, 9–10 mice per group were analyzed. Numbers in the
graph indicate the number of mice that rejected the tumor per number of
analyzed mice. (A–F, histograms) To analyze whether the peripheral lym-
phocytes were derived from donor or recipient BM, the up-regulation of
MHC class II on splenic B cells in response to IL-4 was tested. Spleen
cells from untreated mice of each experimental group were stimulated
with 2 ng/ml recombinant IL-4 for 16 h or were left untreated. The
expression of MHC class II on B220 cells was determined by flow cy-
tometry. Red lines show MHC II expression on untreated B220 cells
and blue lines show MHC II expression after incubation with IL-4. An
isotype-matched control antibody was used to verify staining specificity
(unpublished data). One representative experiment out of two is shown.
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tion. This mortality was not seen in this form in the other
experimental groups and requires further investigation.
Tumor Stroma Fibroblasts Are Differently Activated in IL-4–
secreting Tumors of WT and IL-4R Mice. Next, we
aimed to identify the non-BM–derived cell population re-
sponsible for the rejection of IL-4–secreting tumors. As-
suming that IL-4 exerted its antitumor effect locally and has
pronounced effects on fibroblasts, we analyzed tumor
stroma fibroblasts. WT and IL-4R/ mice were injected
with 107 J558-IL-4 or parental J558L cells and tumors were
removed 6 d later. Tumor sections were stained with the
mAb ER-TR7 that is specific for fibroblasts/extracellular
matrix (24). As shown in Fig. 3, ER-TR7 staining was vis-
ible in J558L and J558-IL-4 tumors of both WT and IL-
4R/ mice, indicating that fibroblasts were recruited by
the tumor independently of IL-4. However, J558-IL-4 tu-
mors derived from WT mice clearly showed the strongest
ER-TR7 staining (Fig. 3 A) compared with J558-IL-4 tu-
mors from IL-4R/ mice (Fig. 3 B) and J558L tumors
from WT (Fig. 3 C) and IL-4R/ mice (Fig. 3 D). Inter-
estingly, ER-TR7 staining in J558-IL-4 tumors from IL-
4R/ mice and J558L tumors from WT and IL-4R/
mice was seen as a lining completely surrounding lumen-
containing structures typical for blood vessels (Fig. 3, B–D,
arrows). Despite the more intense staining, these structures
were lacking in J558-IL-4 tumors of WT mice. It is known
that solid tumors need to induce angiogenesis to receive
nutrients and oxygen and that mesenchymal cells contrib-
ute to angiogenesis by intima formation (25). The more in-
tensive ER-TR7 staining in J558-IL-4 tumors from WT
mice and its absence from the luminal structures suggested
that tumor infiltrating fibroblasts responding to IL-4 were
in a different activation state than those not responding to
IL-4. To support this interpretation, RAG2/ and
RAG2//IL-4R/ mice were injected with J558-IL-4
cells. Tumors were removed and sectioned when they had
reached a size of 1 cm in diameter. As shown in Fig. 3 E, a
local accumulation of collagen I forming regular structures
in tumors derived from RAG2/ but not in those derived
from RAG2/  IL-4R/ mice, could be observed.
When consecutive sections were stained with ER-TR7, a
similar staining pattern as observed with collagen I–specific
antibodies was observed (unpublished data). ER-TR7 and
collagen staining in parental J558L tumors of WT and
IL-4R/ mice was similar to that of J558-IL-4 tumors in
IL-4R/ mice (unpublished data). Together, the data sug-
gested that the tumor stroma fibroblasts were differently ac-
tivated in the absence or presence of IL-4 or IL-4R.
IL-4R Expression by Tumor Stroma Fibroblasts Is Sufficient
for Tumor Rejection. To analyze whether there was a causal
relationship between the altered activation state of tumor
stroma fibroblasts in response to IL-4 and tumor rejection,
fibroblasts were isolated from lungs of WT and IL-4R/
mice. 85–95% of the cells were positive for fibronectin and
collagen I after eight passages in vitro (unpublished data).
106 J558-IL-4 cells were coinjected with either 106 WT or
IL-4R/ fibroblasts into IL-4R/ mice and tumor growth
was measured. As shown in Fig. 4 A, 50% (three out of six)
of IL-4R/ mice rejected tumors when WT fibroblasts
were coinjected with the tumor cells. In contrast, all tumors
(five out of five) grew when the fibroblasts were derived
from IL-4R/ mice (Fig. 4 B). The fact that IL-4R/
mice receiving WT fibroblasts in addition to tumor cells re-
jected tumors less efficiently than IL-4R/ 
 WT BM
chimeric mice indicates that either the number of fibroblasts
used for the mixing experiment was not optimal or that
Figure 3. Fibroblasts in J558-IL-4 tumors of WT mice have an altered
phenotype. WT (A and C) and IL-4R/ mice (B and D) were injected s.c.
with 107 J558-IL-4 (A and B) or J558L cells (C and D) and tumors were re-
moved 6 d later. Tumor tissue sections were stained with a mAb that stains
fibroblasts/extracellular matrix (ER-TR7). Arrows indicate staining around
lumen-containing structures typical for blood vessels. (E and F) 2  106
J558-IL-4 cells were injected s.c. into (E) RAG2/ and (F) RAG2//
IL-4R/ mice and tumors were removed at 1 cm in diameter. Because
the tumors grew with different kinetics in IL-4R–deficient and IL-4R–
competent mice (see Fig. 1), they were removed from RAG2//IL-4R/
mice at day 8 and from RAG2/ mice at day 30. Tumor tissue sections
were stained with a mAb specific for collagen I. Representative sections for
four tumors analyzed per group are shown. 100.
Figure 4. IL-4 responsiveness of fibroblasts in the tumor is sufficient
for rejection of J558-IL-4 cells. 106 lung fibroblasts from (A) WT or (B)
IL-4R/ mice were mixed with 106 J558-IL-4 cells, injected s.c. into
IL-4R/ mice, and tumor growth was measured. Combined data from
two independent experiments with two to three mice/group are shown.
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IL-4R expression by other, non-BM–derived cells contrib-
uted to tumor rejection. Together, our data demonstrate
that IL-4 responsiveness of tumor stroma fibroblasts is suffi-
cient for rejection of IL-4–secreting tumors.
Discussion
Fibroblasts are consistently described as tumor promot-
ing (10–15). Therefore, the major finding in this study was
that the modulation of tumor stroma fibroblasts was suffi-
cient for tumor rejection. Our data also challenge the cur-
rent view concerning the mechanism of tumor rejection by
IL-4. We think that the mechanism to interfere with the
tumor’s effort to establish the necessary stroma follows a
general scheme during immune-mediated rejection of tu-
mor cells injected as a cell suspension that is not only ob-
served during IL-4–mediated tumor rejection. However,
the target cell type(s) may differ in different models, which
can be best illustrated if tumor rejection by IL-4 and IFN
are compared. Both cytokines, even though often de-
scribed as counter-players or antiinflammatory and pro-
inflammatory, respectively, can mediate tumor rejection if
they are expressed by adoptively transferred CD4 T cells
(26–29), CD8 T cells (30–33), or transfected tumor cells
(2, 3). Because the latter model somehow mimics the local
production of cytokines by adoptively transferred T cells
homing to the tumor site, it was used here. In a redundant
fashion, for tumor rejection induced by either cytokine, re-
sponsiveness of non-BM–derived stroma cells is sufficient
(Fig. 2 F and 28). However, IFN acts (directly or indi-
rectly) on endothelial (CD31) cells and inhibits tumor-
induced angiogenesis by arresting CD31 cells at the border
between tumor and adjacent tissue in an IFN-dependent
fashion (28, 34). The IL-4 produced by the tumor, in con-
trast, appears to act primarily on fibroblasts. Fibroblast sub-
populations and in particular those in tumors are still poorly
characterized (7, 8) but the participation of mesenchymal
cells in angiogenesis, e.g., by provision of extracellular ma-
trix, is known. The immunohistochemical stainings in Fig.
3, B–D, suggest that those fibroblasts attracted by tumor
cells in IL-4R/ mice contributed to blood vessel forma-
tion. This function was impaired in IL-4–producing tu-
mors of WT mice, shown by the absence of lumen-con-
taining blood vessels that has been described by Di Carlo et
al. (35). The assumption that IL-4–activated fibroblasts do
not participate in tumor blood vessel formation is sup-
ported by the observation that IL-4 inhibits angiogenesis
(36, 37). Therefore, it appears that the tumor rejection
mechanisms induced by IL-4 and IFN culminate through
different cellular targets in the same pathway. However, a
deeper understanding of the role of fibroblasts during tu-
mor growth or rejection requires a better characterization
of the phenotype of IL-4R/ versus IL-4R/ tumor
stroma fibroblasts. In any case, there is growing evidence
from different models that the primary target during im-
mune-mediated tumor rejection is the stroma and not the
tumor. In this regard, our data could explain how adop-
tively transferred, IL-4–expressing T cells reject tumors
(27, 29, 30, 32, 38), namely by targeting fibroblasts and
interfering with the establishment of a tumor stroma.
Whether IL-4 can inhibit the pro-tumorigenic function of
fibroblasts only in the early phase of tumor stroma forma-
tion or also at later time points is not known. Furthermore,
if data based on tumor transplantation experiments can be
used to explain phenomena in spontaneous tumors, our re-
sults could explain why spontaneous solid tumors virtually
never express substantial amounts of IL-4.
It is important to emphasize that we do not want to ex-
clude other non-BM–derived stromal cell types in addition
to fibroblasts that have to respond to IL-4 to support tumor
rejection. Interestingly, it has been shown that endothelial
cells in IL-4–producing tumors express adhesion molecules
like vascular cell adhesion molecule and CD62E that are not
expressed on endothelial cells in the parental tumor (35).
The lack of their contribution could explain why only 50%
of the IL-4R/ mice coinjected with WT fibroblasts and
J558-IL-4 cells rejected the tumor (Fig. 4 A), whereas all
BM chimeric mice expressing IL-4R only on non-BM–
derived cells rejected the IL-4–producing tumor (Fig. 2 F).
However, we do not know whether the number of co-
injected fibroblasts was optimal and how long the fibroblasts
were functional and survived in vivo. Because IL-13 also
uses the IL-4R, induces rejection of transfected tumor cells,
and can be induced by IL-4 (39), we cannot exclude that
host IL-13 contributed to IL-4–dependent tumor rejection.
It has been known for a while that the growth of IL-4–
producing tumors is, depending on the level of IL-4 ex-
pression, long-term suppressed in T cell–deficient or CD8
T cell–depleted mice. However, such tumors finally grow
out showing that the presence of T cells is critical in the
later phase of the IL-4–mediated antitumor response (5–7
and Fig. 1). The comparison of the WT 
 WT and WT 

IL-4R/ mice (Fig. 2, C and E) demonstrated that the
rapid formation of tumor burden was inhibited by IL-4–
responsive, non-BM–derived cells in the very early phase of
the antitumor response. This firmly establishes a hypothesis
originally put forward by Hock et al. (6). They suggested
that T cell–independent inhibition of tumor burden of IL-
4–secreting tumors allowed T cells to become activated
and effective without necessarily being stimulated by IL-4
that is produced by the tumor. One cannot exclude, how-
ever, that IL-4 acted on T cells because WT 
 IL-4R/
chimeras also rejected the tumor. Which BM-derived cells
had to express IL-4R is not known. However, BM cells are
a complementary source of smooth muscle-like cells during
neointimal formation after BM transplantation (40) and fi-
broblast-like cells isolated from peripheral blood, termed fi-
brocytes, which rapidly enter sites of tissue injury and pro-
mote angiogenesis, have been described (41–43). Which
physiological response does IL-4/fibroblast-mediated tu-
mor rejection resemble? Fibroblasts are critically involved
in wound healing, a process that is supported by IL-4 (44).
Because tumors have remarkable similarities with healing
wounds (45), we suggest that IL-4–mediated tumor rejec-
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tion, at least in part, resembles a wound healing response
during which IL-4–activated fibroblasts control normal tis-
sue homeostasis that is defective in progressing tumors
(8, 9). Together, our data suggest that IL-4–activated fibro-
blasts do not contribute to formation of a pro-tumorigenic
environment, probably because they cannot participate in
tumor-induced angiogenesis. This prevents rapid tumor
burden and provides sufficient time for the activation of T
cells that are required for complete tumor rejection but
must not necessarily be able to respond to IL-4.
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